# Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

> **NCT04806451** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 103 (actual)

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Crinecerfont
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04806451
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-25
- **Primary completion:** 2023-03-10
- **Final completion:** 2027-08
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806451, "Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04806451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*